FFO
MIRA icon

Fortitude Family Office’s MIRA Pharmaceuticals MIRA Stock Holding History

Fortitude Family Office’s Portfolio MIRA Stock Details MIRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-773
Closed -$935 – 2080
2025
Q2 		$935 Buy
+773
New +$893 ﹤0.01% 1547

Other funds holding MIRA

CSI
Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
FAB
First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JWCA
J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return

Fortitude Family Office's MIRA Position: Q3 2025 in Review

Fortitude Family Office sold out of MIRA Pharmaceuticals (MIRA) in Q3 2025, closing a stake of 773 shares — an estimated $935 sold.

Fortitude Family Office first reported a position in MIRA in Q2 2025 and held it in 1 quarter. The position peaked at $935 in Q2 2025. 29 funds tracked by Wall St. Rank hold MIRA as of Q3 2025.

  • Fortitude Family Office reported no remaining MIRA Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Fortitude Family Office sold 773 MIRA Pharmaceuticals shares in Q3 2025, an estimated $935.
  • Fortitude Family Office first reported a position in MIRA Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Fortitude Family Office's MIRA Pharmaceuticals position peaked at $935 in Q2 2025.
  • 29 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.